|
Hemato-oncology
Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
Eun Kyo Joung, Ji Hyun Yang, Sooeun Oh, Se Jun Park, Jieun Lee
Korean J Intern Med. 2021;36(1):182-193. Published online February 28, 2020
Background/Aims: Sequential monotherapy is recommended for anthracycline-and taxane-resistant metastatic breast cancer (MBC), but combination chemotherapy is considered in patients with visceral crisis. Cisplatin-doublet chemotherapy is a combination regimen for MBC, but prolonged treatment is chall..
|
|
|
Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
Hye Sung Won, Yong Seok Kim, Jeong Soo Kim, Eun Deok Chang, Sae Jung Na, In Yong Whang, Dong Soo Lee
Korean J Intern Med. 2020;35(6):1489-1496. Published online February 21, 2020
Background/Aims: We evaluated the efficacy of docetaxel and epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer and assessed the predictive factors for response to neoadjuvant chemotherapy and prognostic factors related to relapse-free survival.
Methods: Forty patients who rece..
|
|
|
Metabolic comorbidities and medical institution utilization among breast cancer survivors: a national population-based study
Jaesung Heo, Mison Chun, Young-Taek Oh, O Kyu Noh, Logyoung Kim
Korean J Intern Med. 2020;35(2):421-428. Published online September 5, 2019
Background/Aims: We investigated metabolic comorbidity status and patterns of medical institution utilization among breast cancer survivors using medical claims data from the Health Insurance Review and Assessment Service (HIRA).
Methods: Using claims data obtained from the HIRA, we selected breast..
|
|
|
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
Mi Hwa Heo, Hee Kyung Kim, Hansang Lee, Ji-Yeon Kim, Jin-Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Korean J Intern Med. 2019;34(5):1100-1106. Published online March 16, 2018
Background/Aims: We conducted a retrospective analysis of the clinical activity of fulvestrant in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) previously treated with endocrine therapy and/or chemotherapy..
|
|
|
Endocrinology-metabolism
Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients
Da Hea Seo, Yongin Cho, Sujin Lee, Seho Park, Seung-Il Kim, Byeong Woo Park, Yumie Rhee
Korean J Intern Med. 2019;34(3):579-587. Published online August 25, 2017
Background/Aims: The aromatase inhibitors (AIs) are well known anti-hormonal therapy in endocrine-responsive breast cancer patients. It can lead to dyslipidemia and be the risk factor of cardiovascular disease due to low estrogen level. However, some recent studies comparing AIs with placebo have sh..
|
|
|
Acute cor pulmonale due to pulmonary tumor thrombotic microangiopathy in two patients with breast cancer
Sung Young Moon, Kang Hoon Lee, Jong Sik Lee, Hyun Suk Yang, Hong Ghi Lee, Yo Han Cho, So Young Yoon
Korean J Intern Med. 2017;32(1):190-194. Published online February 3, 2016
|
|
|
Trastuzumab-associated autoimmune thyroid disease in a patient with metastatic breast cancer
Hong Ki Min, In-Ho Kim, Jae Young Kim, Tae-hyun Ban, Kyung Hoon Kim, Jeonghoon Ha, Jung-Hoon Kim
Korean J Intern Med. 2016;31(3):608-611. Published online February 18, 2016
|
|
|
Hepatitis B Reactivation During Adjuvant Anthracycline-Based Chemotherapy in Patients with Breast Cancer: A Single Institution's Experience
Min Kyoung Kim, Jin Hee Ahn, Sung-Bae Kim, Young-Suk Im, Soon Im Lee, Sei-Hyun Ahn, Byung Ho Son, Gyungyub Gong, Hak-Hee Kim, Woo Kun Kim
Korean J Intern Med. 2007;22(4):237-243. Published online December 20, 2007
BackgroundThe objectives of this study were to determine the incidence, outcome and risk factors for HBV reactivation in HBsAg positive breast cancer patients while on anthracycline -based adjuvant chemotherapy. MethodsWe retr..
|
|
|
